检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]山东省日照市人民医院介入放射科,276826
出 处:《中国临床实用医学》2009年第10期26-27,共2页China Clinical Practical Medicine
摘 要:目的评价经导管超选择栓塞术在耳鼻喉疾病中的临床应用价值。方法2005年11月至2009年1月间,14例患有耳鼻喉疾病的患者应用超选择血管栓塞术诊治,男13例,女1例。年龄13~79岁,单纯严重鼻出血4例,鼻咽癌及上颌窦癌致顽固出血各2例,扁桃腺手术术后出血1例,鼻咽纤维血管瘤术前栓塞5例。结果9例严重鼻出血中经超选择血管栓塞治疗后,出血均获得有效的控制,5例鼻咽纤维血管瘤术前栓塞肿瘤供血动脉均获成功,减少了术中出血量,手术野清晰,实体瘤更易于辨认、切除。所有行超选择血管栓塞术的患者均未发生严重并发症。结论超选择血管栓塞术是诊断和治疗严重耳鼻喉出血的安全、有效的方法。鼻咽纤维血管瘤术前行超选择血管栓塞,能有效地减少术中出血量,有利于提高手术的成功率,减少并发症。Objective To evaluate clinical applicable value of transcatheter superselective embolization in otolaryngology disease. Methods From November 2005 to January 2009, there were 14 cases who suffer from otolaryngology disease received diagnosis and treatmentt using superselective embolization, including 13 male cases and one female case. Their age were from 13 to 79 years old. 4 cases were simple severe nosebleed, stubborn nosebleed from nasopharyngeal darcinoma and carcinoma of the maxillary sinus had 2 cases separately, one case tonsil postoperative nosebleed ,5 cases nasopharynx fibroangioma preoperotive embolization. Results Having received through superselective embolization, severe nosebleed in 9 cases were effective controled, tumour bloodsupply artery were preoperotive embolism successfully in 5 cases nasopharynx fibroangioma, the operation became more easy and intraoperative hemorrhage became less. There had no severe complicating disease in all cases. Conclusion Superselective embolization is a safe and effective method to make a diagnosis and give treatment for severe otolaryngology hemorrhage. Intraoperative hemorrhage woule be reduced and mission success rate of operations raised, severe complicating disease reduced, if cases received super-select embolism method before nasopharynx fibroangioma operotions.
分 类 号:R76[医药卫生—耳鼻咽喉科]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.30